Executive summary: U.S. Patent 8,859,510 is a narrow, polymorph-defined, method-of-treatment claim set that ties oral dosing for bacterial (notably Clostridia, including C. difficile) to a specific X-ray diffraction (XRD) signature (2θ peaks at 7.7°, 15.0°, and 18.8° ±0.2°) of a Formula I tiacumicin polymorphic form. The enforceable scope is driven by (i) the polymorph identification via XRD peak positions and (ii) high-percentage composition thresholds (≥85% up to ≥99% by weight of “tiacumicins”). Attack surfaces for generics and licensors are limited to whether their polymorph matches the claimed diffraction pattern and whether the tested polymorph purity meets the claimed wt% cutoffs; route of administration and the bacterial target also matter for full claim coverage.
What does US Patent 8,859,510 claim for tiacumicin polymorph treatment of bacterial infections?
Core claim thesis (independent claim 1): A method of treating a bacterial infection by administering a polymorph-characterized tiacumicin composition to a subject in need, where the polymorph is defined by an XRD powder pattern with peaks at: 2θ = 7.7°, 15.0°, 18.8° ±0.2°. The composition contains a “polymorphic form of a compound of Formula I.”
Scope drivers in claim 1
- Claim object: method of treatment of bacterial infection in a subject.
- Required active state: a specific polymorphic form of Formula I.
- Polymorph definition: XRD peak positions (two fixed peaks at 7.7° and 15.0°, one peak with a tolerance band at 18.8° ±0.2°).
- Therapeutic framing: “therapeutically effective amount” is present, but the polymorph definition and infection target are the structural limits that determine infringement.
- Composition is not further limited in claim 1 beyond being a composition comprising the polymorphic form. Dependent claims then add oral route, dosage range, solid dosage form, and wt% thresholds.
Interpretation consequences for infringement
- A defendant can design around by using a polymorph that produces a substantially different XRD peak set under relevant measurement conditions, or by using a mixture where the claimed polymorph falls below the wt% thresholds in dependent claims (where those dependent claims are asserted).
- Claim 1 is not expressly limited to Clostridia in its independent portion, so if the claimed polymorphic form is administered to treat any bacterial infection, claim 1 can still be implicated. Dependent claims narrow the bacterial class (Clostridia/C. difficile) and the infection site (gastrointestinal).
What are the dependent claim limitations and why they matter?
Oral route and dose range
- Claim 2: administration is oral.
Infringement impact: a non-oral formulation (e.g., parenteral) would avoid claim 2 while still potentially implicating claim 1 if claim 1 is asserted without the route-specific dependence.
- Claim 3: amount about 0.001 mg to about 1000 mg.
Infringement impact: typical commercial dosing could fall within or outside this wide range; the practical question is whether the accused regimen is characterized as “about” the claimed range.
Solid dosage form
- Claim 4: composition is a solid dosage form.
Infringement impact: liquid oral solutions/suspensions are outside claim 4 but could still fall under claim 1 (and claim 2 if oral is asserted) if “composition comprising” is read broadly enough; however, solid dosage form is a distinct dependent limitation.
Polymorph purity thresholds (tiacumicins wt%)
Claims 5–9 progressively require that the polymorphic form is present in the composition at at least a specific fraction of the total tiacumicins:
- Claim 5: ≥ 85% of total weight of tiacumicins
- Claim 6: ≥ 90%
- Claim 7: ≥ 93%
- Claim 8: ≥ 95%
- Claim 9: ≥ 99%
Infringement impact: These thresholds are high and can be outcome-determinative. A generic developer who uses a manufacturing process that yields a multi-polymorph product, or a polymorph mixture with residual other forms, may fall below the asserted cutoff. If the asserted dependent claim is the one tied to the highest purity threshold, the purity characterization method (what counts as “tiacumicins,” which forms are quantified, and how “total weight” is computed) becomes critical.
Bacterial target narrowing
- Claim 10: bacterial infection caused by Clostridia
- Claim 11: infection caused by Clostridium difficile
- Claim 12: gastrointestinal infection
- Claim 13: specifically Clostridium difficile infection
Infringement impact: For labeling and off-label use disputes, claim 1 may be broad enough to cover non-Clostridia infections if the accused drug is used for them; but many enforcement actions will rely on narrower dependent claims that align with marketed indications (C. difficile, gastrointestinal).
How is the polymorphic form defined in US 8,859,510, and what does that mean for design-around?
Featured-snippet answer: The polymorph is defined by a powder XRD pattern with peaks at 2θ 7.7°, 15.0°, and 18.8° ±0.2°.
XRD peak-based polymorph definition: litigation risk profile
XRD-defined polymorph claims are often attacked on:
- measurement reproducibility and instrument settings
- sample preparation effects (particle size, preferred orientation, hydration state)
- whether claimed peaks appear at or within the tolerance band
- whether the accused form is truly the same polymorph or an isostructural variant
Here, the claim includes a strict tolerance only for 18.8° (±0.2°), while 7.7° and 15.0° are specified without stated tolerance in the text provided. Practically, that gives:
- a clearer “window” for the 18.8° peak
- less explicit tolerance guidance for the other two peaks, which can still become a measurement and claim-construction battleground
Purity and mixture containment
The dependent claims embed wt% thresholds for the polymorph’s presence “with at least about X% of the total weight of tiacumicins.” This creates a second design-around axis:
- even if XRD peak positions match, insufficient polymorph fraction could avoid dependent-claim coverage (and depending on enforcement theory, may also be argued to defeat whether the composition “comprising” satisfies the full limitation set).
What infections and indications does the claim language cover for Clostridia and C. difficile?
Direct scope map based on claims 10–13
- Clostridia infections: claim 10
- Clostridium difficile infections: claim 11 and claim 13
- Gastrointestinal infection: claim 12
- C. difficile + gastrointestinal context: claim 13
Coverage implications for product labeling and off-label use
- If a product is approved/marketed for C. difficile, the dependent claim set (10–13) aligns tightly with common enforcement targets.
- If a product is used off-label for other bacterial infections, claim 1 can still be asserted because independent claim 1 is not limited to Clostridia.
How strong is the patent estate around polymorph XRD signatures for tiacumicins—what are the likely claim-construction focus points?
Key enforceability levers
- The polymorph definition is the central limiter: infringement depends on establishing that the accused polymorph is characterized by the exact XRD peaks at the specified 2θ values (with tolerance as specified).
- The “tiacumicins” purity thresholds are high: a high-purity manufacturing process is needed to satisfy dependent claims 5–9.
- Dependent claim stacking matters: if litigated claims are asserted as dependent (e.g., claim 7), the accused product must meet the base claim 1 plus the additional limitations (oral/solid, wt% threshold, and/or infection type).
Likely construction battlegrounds (based on the claim text structure)
- whether “powder X-ray diffraction pattern” is evaluated by peak presence only or also requires matching relative intensities and peak shapes (not stated in the claims provided)
- the practical meaning of “about” in “therapeutically effective amount” and in the wt% language (“at least about 85%,” etc.)
- whether “total weight of tiacumicins” includes only tiacumicin-related components present in the composition or broader impurities (not defined in the claims provided)
What are the patent landscape questions for US 8,859,510 in an Orange Book / generic entry scenario?
Featured-snippet answer: This patent reads like a composition polymorph + method-of-treatment barrier, so generic entry risk turns on whether the generic’s tiacumicin polymorph matches the claimed XRD peaks and whether the product meets the claimed polymorph purity thresholds (where asserted), alongside indication and route-of-administration alignment.
Practical entry risk framework (claim-by-claim)
- Route-of-administration risk: If the generic is oral, it does not avoid claim 2. If non-oral, it can avoid claim 2 while still potentially implicating claim 1.
- Dosage form risk: Solid dosage form avoids/aligns with claim 4; liquid oral forms would aim to avoid claim 4.
- Polymorph matching risk: If the accused solid contains a different polymorph not characterized by the claimed 2θ pattern, infringement arguments focus on analytical data.
- Purity risk: If the wt% of the claimed polymorph is below a cutoff asserted in litigation (85/90/93/95/99), infringement on dependent claims fails.
Orange Book linkage (what can and cannot be inferred from claim text alone)
The claims do not identify an NDC, branded drug name, reference listed drug (RLD), or FDA approval status. Without that bibliographic mapping to an FDA listing, it is not possible to state Orange Book listing status, listed patent numbers tied to specific dosage forms, or any Paragraph IV/Biosimilar exclusivity status.
Which companies would likely be positioned to challenge or license around US 8,859,510?
No party names, litigants, settlements, or licensing deals are provided in the prompt, and the patent text provided does not identify assignees, inventors, or the underlying compound identity beyond “tiacumicins” and “Formula I.” Without those anchors, any attribution would be speculation.
What is the geographic and claim-scope impact of a single US method patent like 8,859,510?
Baseline: US 8,859,510 is a United States patent, so infringement is controlled under US law for acts committed in the US (including importation, offer for sale, and use depending on the statutory hook). The claim language indicates a US enforceable method-of-treatment barrier: practicing the method by administering the polymorph-defined composition to treat the covered bacterial infections within the US.
International coverage depends on whether there are corresponding filings (family members) in other jurisdictions, which are not provided here.
How do you evaluate generic launch scenarios against a polymorph-defined tiacumicin method patent?
Launch scenario matrix using only the limitations present in the claims provided
- Scenario A: Same polymorph XRD + oral + solid + purity ≥ asserted cutoff + treated indication (C. difficile or Clostridia if dependent claim used)
High infringement risk across claims 1–9 and potentially 10–13.
- Scenario B: Same polymorph XRD but purity below asserted cutoff
Likely avoids asserted dependent wt% claims; claim 1 may still be asserted if purity is not part of independent claim 1 as written (it is not).
- Scenario C: Different polymorph (XRD peaks not matching the claimed 2θ signature)
Primary design-around; strongest defense against both independent and dependent polymorph-defined coverage, subject to claim construction on what “characterized by” requires.
- Scenario D: Non-oral administration
Avoids claim 2; may still risk claim 1 if oral is not required in asserted independent claim coverage.
- Scenario E: Non-solid dosage form
Avoids claim 4; still risks claim 1 and potentially claim 2 depending on route.
Key Takeaways
- US 8,859,510 is centered on a polymorph-specific tiacumicin composition defined by powder XRD peaks at 2θ 7.7°, 15.0°, and 18.8° ±0.2°.
- The independent claim is a method-of-treating bacterial infections via administration of that polymorph-defined composition; dependent claims narrow to oral, solid dosage form, a dose range, and high polymorph purity thresholds (≥85% to ≥99% of total tiacumicins).
- Dependent claims add specific bacterial scopes: Clostridia and C. difficile, and a gastrointestinal infection context.
- For generic or follow-on entry, the practical infringement questions are: does the accused product contain the same XRD-characterized polymorph, and does it meet any asserted wt% purity threshold, plus whether the challenged regimen matches the oral/solid and indication limitations in asserted dependent claims.
FAQs
1) What XRD peak pattern must match to satisfy US 8,859,510 polymorph limitation?
Peaks at 2θ 7.7°, 15.0°, and 18.8° ±0.2°.
2) Does US 8,859,510 require oral dosing to infringe independent claim 1?
No; oral is added in dependent claim 2. Independent claim 1 text provided does not impose a route limitation.
3) What purity thresholds are claimed for the polymorphic form of Formula I in tiacumicins?
Dependent claims require at least 85%, 90%, 93%, 95%, or 99% of the total weight of tiacumicins, depending on the asserted claim.
4) Is C. difficile treatment explicitly covered?
Yes. Clostridium difficile is covered in dependent claims 11 (C. difficile infection) and 13 (C. difficile infection as a gastrointestinal infection framing).
5) What is the strongest design-around for a developer targeting this patent?
Using a tiacumicin polymorph that is not characterized by the claimed powder XRD peak pattern, and, where dependent wt% claims are asserted, ensuring the claimed polymorph fraction does not meet the asserted purity cutoff.
References
- US Patent 8,859,510 (claims as provided in the prompt).
